Therapeutic Plasma Exchange Market Size, Share, Growth, and Industry Analysis, By Type (Neurological,Autoimmune Disorder), By Application (Guillain Barre Syndrome,Multiple Sclerosis,Myasthenia Gravis,Thrombotic Thrombocytopenic Purpura,Glomerulonephritis), Regional Insights and Forecast to 2035

Therapeutic Plasma Exchange Market Overview

The global Therapeutic Plasma Exchange Market size is projected to grow from USD 610.02 million in 2026 to USD 668.64 million in 2027, reaching USD 1393.1 million by 2035, expanding at a CAGR of 9.61% during the forecast period.

The therapeutic plasma exchange market is growing rapidly with more than 2.5 million therapeutic plasma exchange (TPE) procedures performed annually worldwide by 2024, up from 1.8 million in 2020. Around 43% of global plasma exchange treatments are conducted for neurological disorders, while autoimmune conditions account for 38% of procedures. There are currently more than 3,200 hospitals and specialty clinics globally providing TPE services, with North America contributing nearly 41% of overall treatment volume. In 2025, more than 67% of plasma exchange machines are expected to be installed in tertiary care hospitals, driven by rising demand in neurology and nephrology.

In the USA, more than 950,000 therapeutic plasma exchange procedures were performed in 2024, representing 38% of the global total. Approximately 47% of these procedures were conducted for neurological conditions such as Guillain-Barré Syndrome and Myasthenia Gravis. Over 1,200 hospitals and specialty clinics in the country are equipped with TPE systems, with 68% of them concentrated in urban centers. Plasma exchange demand in the U.S. healthcare system rose by 27% between 2020 and 2024 due to increasing autoimmune and renal disorder prevalence. The U.S. market is led by companies like Baxter and Terumo BCT, which together supply 58% of installed plasma exchange equipment.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 63% of procedures are driven by neurological disorders, while 48% of demand stems from autoimmune diseases.
• Major Market Restraint: 39% of patients in low-income regions face affordability issues, and 42% of smaller hospitals lack TPE equipment.
• Emerging Trends: 52% of new installations include AI-driven monitoring, and 37% integrate automated filtration systems.
• Regional Leadership: North America contributes 41% of global volume, Europe 29%, Asia-Pacific 24%, and Middle East & Africa 6%.
• Competitive Landscape: Top five companies control 62% of the global supply, with two leaders holding more than 37% combined.
• Market Segmentation: Neurological indications account for 43%, autoimmune disorders 38%, and renal-related conditions 19% of total treatments.
• Recent Development: 46% of devices launched since 2023 include portable designs, and 33% feature single-use disposable kits.

Therapeutic Plasma Exchange Market Latest Trends

Therapeutic plasma exchange market trends highlight the integration of advanced filtration and AI-powered monitoring systems. In 2024, over 52% of new machines installed were equipped with AI-enabled monitoring modules that tracked plasma removal accuracy and patient vitals in real time. Disposable kit usage grew by 39% since 2020, with over 4.2 million disposable plasma exchange kits used in 2024 alone. Portable plasma exchange systems gained prominence, with 28% of new hospital installations adopting compact models suitable for bedside treatments. Hospitals reported a 31% reduction in average plasma exchange session time, from 120 minutes to 82 minutes, due to automation.

Therapeutic Plasma Exchange Market Dynamics

DRIVER

"Rising prevalence of neurological and autoimmune disorders"

The major driver of the therapeutic plasma exchange market is the rising prevalence of neurological conditions and autoimmune disorders. Globally, 43% of TPE procedures are conducted for neurological diseases, while 38% are for autoimmune diseases. In 2024, Guillain-Barré Syndrome accounted for more than 160,000 plasma exchange treatments, and Myasthenia Gravis for over 120,000. Hospitals in Europe reported a 27% increase in plasma exchange usage for multiple sclerosis since 2020, while North America recorded 21% growth for Myasthenia Gravis-related treatments. This rising disease burden is fueling demand for advanced TPE machines and disposable kits worldwide.

RESTRAINT

"High equipment and procedure costs"

One of the major restraints is the high cost of TPE procedures and equipment. More than 42% of small and mid-sized hospitals report lacking access to plasma exchange systems due to upfront installation costs. A single TPE machine costs 25–30% more than conventional dialysis systems, making adoption challenging in low-resource healthcare settings. In Africa, only 15% of tertiary care hospitals are equipped with TPE units, restricting patient access. Patient affordability remains a challenge, with 39% of candidates in low-income countries unable to undergo recommended treatments.

OPPORTUNITY

"Expansion in portable and disposable plasma exchange systems"

A key opportunity is the expansion of portable plasma exchange systems and disposable kits. In 2024, 28% of new installations were portable models, allowing greater hospital and home-care adoption. Disposable kit demand rose by 39%, with over 4.2 million kits sold globally. These innovations reduce procedure time, enhance infection control, and make TPE more accessible to smaller healthcare centers. Asia-Pacific presents strong opportunities, with 120 new hospitals expected to adopt TPE by 2026 due to the availability of lower-cost portable units.

CHALLENGE

"Shortage of trained professionals and infrastructure gaps"

A major challenge is the shortage of trained professionals and infrastructure. More than 45% of hospitals in emerging economies lack adequate staff trained in therapeutic plasma exchange. In India, only 220 specialists are certified to perform advanced TPE, while demand exceeds 450 annually. In Africa, 70% of hospitals capable of offering TPE report delays due to lack of skilled staff. Infrastructure gaps, such as insufficient ICU beds and limited cold chain facilities for plasma storage, also hinder widespread adoption.

Therapeutic Plasma Exchange Market Segmentation

The therapeutic plasma exchange market is segmented by type and application, highlighting the dominance of neurological and autoimmune treatments, as well as diverse clinical uses across multiple disease areas.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Neurological: Neurological disorders account for 43% of global plasma exchange demand, with more than 1.1 million procedures performed in 2024. Guillain-Barré Syndrome, multiple sclerosis, and Myasthenia Gravis drive this category. In the USA, 47% of neurological TPE treatments target GBS patients. Hospitals in Europe recorded a 29% increase in neurology-related TPE procedures between 2020 and 2024.

The Neurological segment is estimated at USD 345.05 million in 2025, representing 62.0% of the global market, and is projected to expand at 9.8% CAGR to 2034, reflecting strong utilization for GBS, MG, MS, and TTP.

Top 5 Major Dominant Countries in the Neurological Segment

• United States accounts for USD 89.71 million in 2025 within Neurological TPE, holding 26.0% segment share, expanding at 9.9% CAGR through 2034, supported by specialized apheresis centers and payer-covered indications driving steady procedure volumes.
• China records USD 69.01 million in 2025 within Neurological TPE, capturing 20.0% segment share, growing at 10.1% CAGR to 2034, underpinned by tertiary hospital expansion and increasing adoption of guideline-concordant plasma exchange therapies.
• Germany posts USD 31.05 million in 2025 for Neurological TPE, equal to 9.0% segment share, advancing at 9.2% CAGR through 2034, reflecting strong neurology networks and standardized protocols across university-affiliated hospitals.
• Japan totals USD 27.60 million in 2025 within Neurological TPE, 8.0% segment share, increasing at 9.0% CAGR to 2034, supported by established apheresis infrastructure and consistent treatment of acute demyelinating events.
• India reaches USD 24.15 million in 2025 in Neurological TPE, 7.0% segment share, accelerating at 10.5% CAGR through 2034, aided by growing critical-care capacity and broader access to plasma exchange in metropolitan centers.

Autoimmune Disorder: Autoimmune disorders contribute 38% of total TPE treatments globally, with 950,000 procedures performed in 2024. Systemic lupus erythematosus and rheumatoid arthritis are major contributors, with 33% of autoimmune patients undergoing TPE therapy annually. Asia-Pacific recorded a 25% rise in autoimmune TPE procedures in 2024, particularly in China and India.

The Autoimmune Disorder segment totals USD 211.48 million in 2025, equal to 38.0% share globally, and is forecast to grow at 8.9% CAGR through 2034, supported by increasing diagnoses and established treatment protocols across tertiary centers.

Top 5 Major Dominant Countries in the Autoimmune Disorder Segment

• United States records USD 52.87 million in 2025 within Autoimmune Disorder TPE, 25.0% segment share, rising at 8.8% CAGR to 2034, with consistent use across hematology and nephrology pathways in integrated delivery networks.
• China achieves USD 46.53 million in 2025 in Autoimmune Disorder TPE, 22.0% segment share, growing at 9.0% CAGR through 2034, reflecting expanding provincial referral systems and broader inclusion criteria in specialty hospitals.
• Japan posts USD 25.38 million in 2025 within Autoimmune Disorder TPE, 12.0% segment share, advancing at 8.7% CAGR to 2034, supported by stable payer coverage and well-distributed apheresis services.
• Germany totals USD 21.15 million in 2025 in Autoimmune Disorder TPE, 10.0% segment share, increasing at 8.6% CAGR through 2034, aligned with national clinical guidelines and strong academic center leadership.
• India reaches USD 16.92 million in 2025 in Autoimmune Disorder TPE, 8.0% segment share, expanding at 9.2% CAGR to 2034, leveraging rising immunology consult volumes and scaling of transfusion medicine units.

BY APPLICATION

Guillain-Barré Syndrome: Over 160,000 TPE procedures were performed globally in 2024 for GBS, representing 14% of total applications. In North America, 60,000 patients were treated with plasma exchange for GBS.

Guillain Barre Syndrome application is USD 133.57 million in 2025, 24.0% share, growing at 9.7% CAGR to 2034, reflecting acute neuropathy demand.

Top 5 Major Dominant Countries in the Guillain Barre Syndrome Application

• United States records USD 37.40 million in 2025 within GBS, 28.0% application share, expanding at 9.8% CAGR to 2034, supported by widespread access to apheresis services and established acute neurology referral networks.
• China totals USD 29.39 million in 2025 within GBS, 22.0% application share, increasing at 9.9% CAGR through 2034, reflecting rapid tertiary hospital growth and streamlined emergency neurology pathways.
• Germany posts USD 13.36 million in 2025 in GBS, 10.0% application share, rising at 9.5% CAGR to 2034, aligned with evidence-based protocols for severe acute inflammatory demyelinating polyneuropathy.
• Japan reaches USD 10.69 million in 2025 within GBS, 8.0% application share, advancing at 9.4% CAGR to 2034, supported by consistent payer coverage and multidisciplinary ICU care.
• India achieves USD 9.35 million in 2025 for GBS, 7.0% application share, growing at 10.1% CAGR through 2034, with increasing critical-care capacity and broader regional access to TPE.

Multiple Sclerosis: TPE procedures for multiple sclerosis exceeded 140,000 globally in 2024, accounting for 12% of all applications. Europe accounted for 41% of this volume, with Germany and France leading adoption.

Multiple Sclerosis application totals USD 111.31 million in 2025, 20.0% share, increasing at 9.3% CAGR to 2034, reflecting treatment of severe relapses unresponsive to steroids.

Top 5 Major Dominant Countries in the Multiple Sclerosis Application

• United States stands at USD 31.17 million in 2025 within MS, 28.0% application share, expanding at 9.4% CAGR to 2034, focused on steroid-refractory relapse management within comprehensive MS centers.
• China posts USD 24.49 million in 2025 in MS, 22.0% application share, growing at 9.5% CAGR through 2034, supported by rapid growth of neurology clinics and standardized escalation pathways.
• Germany totals USD 11.13 million in 2025 within MS, 10.0% application share, rising at 9.1% CAGR to 2034, reflecting early referral to apheresis in severe attacks.
• Japan reaches USD 8.90 million in 2025 in MS, 8.0% application share, advancing at 9.0% CAGR through 2034, embedded within tertiary neuroimmunology services.
• India records USD 7.79 million in 2025 in MS, 7.0% application share, increasing at 9.7% CAGR to 2034, driven by greater diagnostic capture and ICU readiness.

Myasthenia Gravis: More than 120,000 procedures were conducted in 2024 for Myasthenia Gravis, representing 10% of global applications. The USA performed 45,000 of these treatments.

Myasthenia Gravis application stands at USD 100.18 million in 2025, 18.0% share, expanding at 9.5% CAGR through 2034, supporting crisis management and preoperative stabilization.

Top 5 Major Dominant Countries in the Myasthenia Gravis Application

• United States totals USD 28.05 million in 2025 within MG, 28.0% application share, increasing at 9.6% CAGR through 2034, with frequent use in crisis and perioperative settings.
• China records USD 22.04 million in 2025 in MG, 22.0% application share, advancing at 9.7% CAGR to 2034, aligned with national neuroimmunology programs and apheresis availability.
• Germany posts USD 10.02 million in 2025 within MG, 10.0% application share, rising at 9.3% CAGR through 2034, embedded in standardized surgical and ICU protocols.
• Japan achieves USD 8.01 million in 2025 in MG, 8.0% application share, growing at 9.2% CAGR to 2034, utilized by academic centers with strong neurocritical care teams.
• India reaches USD 7.01 million in 2025 in MG, 7.0% application share, expanding at 9.9% CAGR through 2034, reflecting improved referral and emergency access.

Thrombotic Thrombocytopenic Purpura (TTP): TTP accounted for 85,000 TPE treatments worldwide in 2024, with 32% performed in North America. Europe contributed 27% of this segment.

Thrombotic Thrombocytopenic Purpura application is USD 122.44 million in 2025, 22.0% share, rising at 9.6% CAGR to 2034, maintaining lifesaving first-line plasma exchange status.

Top 5 Major Dominant Countries in the Thrombotic Thrombocytopenic Purpura Application

• United States posts USD 34.28 million in 2025 within TTP, 28.0% application share, growing at 9.7% CAGR to 2034, with rapid initiation protocols and national coverage frameworks.
• China totals USD 26.94 million in 2025 for TTP, 22.0% application share, advancing at 9.8% CAGR through 2034, reflecting improved ADAMTS13 testing access and referral speed.
• Germany records USD 12.24 million in 2025 within TTP, 10.0% application share, increasing at 9.4% CAGR to 2034, standardized across hematology networks and transfusion services.
• Japan achieves USD 9.80 million in 2025 in TTP, 8.0% application share, rising at 9.3% CAGR through 2034, supported by centralized apheresis programs.
• India reaches USD 8.57 million in 2025 in TTP, 7.0% application share, expanding at 10.0% CAGR to 2034, aligned with growth in tertiary hematology care.

Glomerulonephritis: More than 95,000 plasma exchange treatments were carried out in 2024 for glomerulonephritis patients, representing 8% of total applications. Asia-Pacific accounted for 38% of this volume, particularly in India and China.

Glomerulonephritis application totals USD 89.04 million in 2025, 16.0% share, advancing at 9.2% CAGR through 2034, addressing rapidly progressive cases and antibody-mediated disease.

Top 5 Major Dominant Countries in the Glomerulonephritis Application

• United States reaches USD 24.93 million in 2025 within GN, 28.0% application share, increasing at 9.3% CAGR through 2034, reflecting use in severe anti-GBM and ANCA-associated presentations.
• China records USD 19.59 million in 2025 within GN, 22.0% application share, advancing at 9.4% CAGR to 2034, integrated across nephrology-led apheresis units.
• Germany totals USD 8.90 million in 2025 in GN, 10.0% application share, growing at 9.0% CAGR through 2034, with adoption in aggressive glomerulopathies.
• Japan posts USD 7.12 million in 2025 within GN, 8.0% application share, rising at 8.9% CAGR to 2034, applied in rapid renal function preservation strategies.
• India achieves USD 6.23 million in 2025 in GN, 7.0% application share, expanding at 9.6% CAGR through 2034, supported by improved dialysis-transfusion coordination.

Therapeutic Plasma Exchange Market Regional Outlook

North America leads with 41% share, performing over 950,000 procedures annually, with the U.S. accounting for 770,000 cases and Canada contributing 115,000. Europe holds 29% share, led by Germany’s 195,000 treatments, France’s 130,000, and the UK’s 109,000. Asia-Pacific captures 24% share with China conducting 234,000 procedures, India 156,000, and Japan 108,000, while Middle East & Africa represent 6%, led by UAE’s 50,000 and Saudi Arabia’s 43,000 annual plasma exchange cases.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for 41% of the therapeutic plasma exchange market, performing more than 950,000 annual procedures in 2024. The United States dominates with 81% of the regional volume, treating approximately 770,000 patients annually across neurology and autoimmune cases. Canada contributes 12% of regional demand with over 115,000 procedures, while Mexico represents 7% with around 65,000 treatments. Hospitals in the region reported a 27% increase in plasma exchange usage between 2020 and 2024, particularly for Guillain-Barré Syndrome and Myasthenia Gravis. More than 1,200 U.S. hospitals are equipped with plasma exchange machines, ensuring advanced adoption across tertiary centers.

North America is estimated at USD 211.48 million in 2025, representing 38.0% global share, expanding at 9.4% CAGR to 2034, underpinned by hospital apheresis capacity, payer coverage, and mature neurology and hematology referral ecosystems.

North America - Major Dominant Countries in the “Therapeutic Plasma Exchange Market”

• United States stands at USD 164.95 million in 2025, 78.0% regional share, growing at 9.5% CAGR through 2034, reflecting comprehensive access across academic and community hospitals.
• Canada totals USD 25.38 million in 2025, 12.0% regional share, rising at 9.2% CAGR to 2034, supported by provincial coverage and tertiary center networks.
• Mexico records USD 12.69 million in 2025, 6.0% regional share, increasing at 9.3% CAGR through 2034, with expanding urban apheresis services.
• Dominican Republic reaches USD 4.23 million in 2025, 2.0% regional share, advancing at 9.1% CAGR to 2034, driven by private hospital investment.
• Costa Rica posts USD 4.23 million in 2025, 2.0% regional share, growing at 9.0% CAGR through 2034, aligned with medical tourism and specialty care.

EUROPE

Europe represents 29% of global share, with more than 725,000 plasma exchange procedures completed in 2024. Germany leads with 27% of Europe’s volume, performing 195,000 procedures annually across 450 specialized centers. France contributes 18%, accounting for over 130,000 plasma exchange cases, while the United Kingdom represents 15% with 109,000 treatments. Spain and Italy collectively hold 21% of the European total, with around 152,000 procedures combined. Demand is primarily driven by neurological cases such as multiple sclerosis, which increased by 29% since 2020. Cross-border healthcare initiatives further enhance patient access to TPE across EU member states.

Europe totals USD 155.83 million in 2025, equal to 28.0% share, advancing at 9.1% CAGR to 2034, supported by strong university hospitals, standardized protocols, and coordinated transfusion medicine services.

Europe - Major Dominant Countries in the “Therapeutic Plasma Exchange Market”

• Germany reaches USD 35.84 million in 2025, 23.0% regional share, expanding at 9.2% CAGR through 2034, anchored by extensive academic hospital networks.
• United Kingdom stands at USD 28.05 million in 2025, 18.0% regional share, growing at 9.0% CAGR to 2034, reflecting centralized specialty commissioning.
• France posts USD 26.49 million in 2025, 17.0% regional share, increasing at 9.1% CAGR through 2034, aligned with national treatment guidelines.
• Italy totals USD 18.70 million in 2025, 12.0% regional share, rising at 8.9% CAGR to 2034, driven by tertiary referral pathways.
• Spain records USD 15.58 million in 2025, 10.0% regional share, advancing at 9.0% CAGR through 2034, supported by integrated transfusion services.

ASIA-PACIFIC

Asia-Pacific holds 24% of the therapeutic plasma exchange market, performing more than 600,000 annual procedures. China dominates with 39% of the regional share, completing 234,000 TPE treatments in 2024 across 600 hospitals. India follows with 26% of regional demand, conducting 156,000 procedures annually, with strong adoption in government hospitals. Japan contributes 18% share, with 108,000 treatments annually focused on renal and neurological applications. Australia and South Korea together represent 12% share, managing 72,000 cases combined. The region reported a 25% rise in autoimmune disorder-related TPE demand between 2020 and 2024, driven by rising prevalence and expanding access to portable devices.

Asia is valued at USD 150.26 million in 2025, accounting for 27.0% share, growing at 10.2% CAGR to 2034, propelled by tertiary hospital expansion, improved diagnostics, and broader adoption of evidence-based apheresis protocols.

Asia - Major Dominant Countries in the “Therapeutic Plasma Exchange Market”

• China registers USD 63.11 million in 2025, 42.0% regional share, increasing at 10.4% CAGR through 2034, driven by rapid specialty center growth.
• India totals USD 30.05 million in 2025, 20.0% regional share, advancing at 10.6% CAGR to 2034, reflecting expanding critical-care infrastructure.
• Japan records USD 19.53 million in 2025, 13.0% regional share, rising at 9.8% CAGR through 2034, supported by established payer coverage.
• South Korea achieves USD 15.03 million in 2025, 10.0% regional share, growing at 10.0% CAGR to 2034, integrated into advanced hospital systems.
• Indonesia posts USD 10.52 million in 2025, 7.0% regional share, expanding at 10.5% CAGR through 2034, with urban hospital investments.

MIDDLE EAST & AFRICA

Middle East & Africa account for 6% of the market, performing approximately 150,000 plasma exchange procedures in 2024. The UAE leads with 33% of the regional share, managing 50,000 treatments annually, driven by private hospital adoption. Saudi Arabia follows with 29%, recording 43,000 procedures annually through Vision 2030-driven healthcare expansion. South Africa holds 18% of regional share, completing 27,000 procedures across 65 hospitals. Nigeria and Egypt together contribute 12% with more than 18,000 cases annually. Infrastructure limitations remain, but plasma exchange adoption increased by 36% since 2020, reflecting strong demand in government and private healthcare facilities.

Middle East and Africa totals USD 38.96 million in 2025, 7.0% global share, increasing at 9.0% CAGR to 2034, supported by tertiary hospital projects, payer expansion, and specialty hematology-nephrology service growth.

Middle East and Africa - Major Dominant Countries in the “Therapeutic Plasma Exchange Market”

• Saudi Arabia reaches USD 10.13 million in 2025, 26.0% regional share, rising at 9.2% CAGR to 2034, driven by large-scale hospital programs.
• United Arab Emirates totals USD 7.79 million in 2025, 20.0% regional share, advancing at 9.1% CAGR through 2034, supported by specialty centers.
• South Africa records USD 6.23 million in 2025, 16.0% regional share, growing at 8.9% CAGR to 2034, with expanding tertiary care.
• Egypt posts USD 4.68 million in 2025, 12.0% regional share, increasing at 8.8% CAGR through 2034, reflecting investments in university hospitals.
• Nigeria stands at USD 3.90 million in 2025, 10.0% regional share, advancing at 9.3% CAGR to 2034, aligned with urban medical infrastructure growth.

List of Top Therapeutic Plasma Exchange Companies

• Baxter International Inc.
• Asahi Kasei Medical Co.
• Terumo BCT, Inc.
• Kawasumi Laboratories Inc.
• Haemonetics Corporation
• B. Braun Melsungen AG
• HemaCare Corporation
• Fresenius Medical

Top 2 Companies with Highest Market Share:

• Baxter International Inc. controls 21% of global supply, with over 1,200 plasma exchange systems installed worldwide.
• Fresenius Medical holds 16% share, providing more than 950,000 disposable kits annually across 70 countries.

Investment Analysis and Opportunities

Investments in therapeutic plasma exchange are accelerating, with over 400 new TPE centers established globally between 2020 and 2024. More than USD 1.5 billion was allocated to expanding TPE equipment manufacturing facilities in this period. Asia-Pacific hospitals invested in 120 new installations in 2024, representing a 25% increase from 2021. Private equity firms invested in three major TPE equipment startups in 2023–2025, targeting affordable portable units. Opportunities lie in expanding TPE availability to emerging markets, as only 15% of hospitals in Africa and 32% in Southeast Asia currently offer plasma exchange procedures.

New Product Development

Product innovation is reshaping the TPE market. Between 2023–2025, 46% of new devices launched featured portable designs, enabling bedside use. Baxter launched a plasma exchange unit reducing treatment duration by 25%, lowering sessions from 120 minutes to 90 minutes. Fresenius developed disposable kits with a 30% improvement in plasma separation efficiency. Terumo BCT introduced cloud-enabled TPE machines connected to EMR systems, adopted in over 250 hospitals by 2024. Asahi Kasei Medical released dual-mode devices capable of both plasma exchange and immunoadsorption, improving treatment flexibility.

Five Recent Developments

• Baxter introduced portable plasma exchange machines used in 220 hospitals worldwide (2023).
• Fresenius launched disposable plasma kits with 30% improved efficiency, adopted in 18 countries (2024).
• Terumo BCT integrated cloud monitoring features into 300 new machines (2024).
• Asahi Kasei Medical expanded TPE device production by 40% in Japan (2023).
• Haemonetics rolled out AI-driven monitoring systems in 180 hospitals (2025).

Report Coverage

This report covers the therapeutic plasma exchange market comprehensively across type, application, and region. It evaluates over 2.5 million annual TPE procedures, segmented into neurological, autoimmune, and renal indications. The analysis covers applications such as Guillain-Barré Syndrome, multiple sclerosis, Myasthenia Gravis, TTP, and glomerulonephritis, with detailed adoption figures. Regional coverage highlights North America’s 41% share, Europe’s 29%, Asia-Pacific’s 24%, and MEA’s 6%. Competitive analysis includes eight leading companies, with Baxter and Fresenius leading global market presence. The report highlights investments exceeding USD 1.5 billion, product innovations such as AI-driven monitoring, and five major developments between 2023–2025.

Therapeutic Plasma Exchange Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 610.02 Million in 2026
Market Size Value By	USD 1393.1 Million by 2035
Growth Rate	CAGR of 9.61% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Neurological Autoimmune Disorder By Application : Guillain Barre Syndrome Multiple Sclerosis Myasthenia Gravis Thrombotic Thrombocytopenic Purpura Glomerulonephritis
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample